Updated cost-of-care estimates for commercially insured patients with multiple sclerosis: Retrospective observational analysis of medical and pharmacy claims data

BMC Health Services Research

Volumn 14, Issue 1, 2014, Pages

  Carroll, Cathryn A ^a   Fairman, Kathleen A ^b   Lage, Maureen J ^c  

^a Teva Pharmaceuticals   (United States)

^b Kathleen Fairman LTD   (United States)

^c HealthMetrics Outcomes Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; DRUG USE; ECONOMICS; FEMALE; HEALTH CARE COST; HUMAN; INSURANCE; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PHARMACOECONOMICS; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ADULT; AGED; DRUG UTILIZATION REVIEW; ECONOMICS, PHARMACEUTICAL; FEMALE; HEALTH CARE COSTS; HUMANS; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84903419607     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-14-286     Document Type: Article

References (30)

1. Multiple sclerosis. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG, N Engl J Med 2000 343 13 938 952
2. How common are the "common" neurologic disorders? Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R, Neurology 2007 68 5 326 337 (Pubitemid 46188246)
3. A comprehensive assessment of the cost of multiple sclerosis in the United States. Whetten-Goldstein K, Sloan FA, Goldstein LB, Kulas ED, Mult Scler 1998 4 5 419 425 (Pubitemid 28515352)
4. Approaches to the management of agents used for the treatment of multiple sclerosis: consensus statements from a panel of U.S. managed care pharmacists and physicians. Miller RM, Happe LE, Meyer KL, Spear RJ, J Manag Care Pharm 2012 18 1 54 62
5. Aspects of Multiple Sclerosis That Relate to Trial Design and Clinical Management. Cohen JA, Rudick RA, Multiple Sclerosis Therapeutics Boca Raton, FL: Taylor & Francis, Cohen JA, Rudick RA, 3 2007 3 22
6. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Goodin DS, Frohman EM, Garmany GP Jr, Halper J, Likosky WH, Lublin FD, Silberburg DH, Stuart WH, van den Noort S, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines, Neurology 2002 58 2 169 178 (Pubitemid 34086933)
7. Expert Opinion Paper: National Clinical Advisory Board of the National Multiple Sclerosis Society. Disease Management Consensus Statement. National Multiple Sclerosis Society, 2008 http://www.nationalmssociety.org/ NationalMSSociety/media/MSNationalFiles/Brochures/ExpOp-Consensus.pdf
8. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. Goldberg LD, Edwards NC, Fincher C, Doan QV, AL-Sabbagh A, Meletiche DM, J Manag Care Pharm 2009 15 7 543 555
9. Economic burden of multiple sclerosis: a systematic review of the literature. Naci H, Fleurence R, Birt J, Duhig A, Pharmacoeconomics 2010 28 5 363 379
10. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. Prescott JD, Factor S, Pill M, Levi GW, J Manag Care Pharm 2007 13 1 44 52 (Pubitemid 46824250)
11. Prevalence, expenditures, utilization, and payment for persons with MS in insured populations. Pope GC, Urago CJ, Kulas ED, Kronick R, Gilmer T, Neurology 2002 58 1 37 43 (Pubitemid 34041935)
12. The pursuit of transparency and quality improvement in cost-effectiveness analysis: a case study in disease-modifying drugs for the treatment of multiple sclerosis. Bell CF, J Manag Care Pharm 2011 17 6 463 468
13. The payer's dilemma: recognizing the uncertainty of clinical and economic evidence at product launch. Watkins JB, Sullivan SD, J Manag Care Pharm 2009 15 2 167 169
14. Initiating drug therapy in multiple sclerosis. Aforismo JF, Pill MW, Prescott JD, American Journal of Pharmacy Benefits 2010 2 1 59 65
15. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States. Asche CV, Singer ME, Jhaveri M, Chung H, Miller A, J Manag Care Pharm 2010 16 9 703 712
16. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Tan H, Cai Q, Agarwal S, Stephenson JJ, Kamat S, Adv Ther 2011 28 1 51 61
17. Glatiramer acetate and interferon beta-1a for intramuscular administration: a study of outcomes among multiple sclerosis intent-to-treat and persistent-use cohorts. Castelli-Haley J, Oleen-Burkey MA, Lage MJ, Johnson K, J Med Econ 2010 13 3 464 471
18. Economic impact of multiple sclerosis disease-modifying drugs in an employed population: direct and indirect costs. Birnbaum HG, Ivanova JI, Samuels S, Davis M, Cremieux PY, Phillips AL, Meletiche D, Curr Med Res Opin 2009 25 4 869 877
19. Potential health care cost savings associated with early treatment of multiple sclerosis using disease-modifying therapy. Curkendall SM, Wang C, Johnson BH, Cao Z, Preblick R, Torres AM, Knappertz V, Gondek K, Clin Ther 2011 33 7 914 925
20. Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US. Ivanova JI, Bergman RE, Birnbaum HG, Phillips AL, Stewart M, Meletiche DM, J Med Econ 2012 15 3 601 609
21. Trisolini MG, Comparison of Multiple Sclerosis Guidelines Underscores Need for Collaboration U.S. Department of Health and Human Services, National Guideline Clearinghouse 2008 http://www.guideline.gov/expert/expert-commentary. aspx?id=16443
22. Guidelines by Topic: Multiple Sclerosis. U.S. Department of Health and Human Services, National Guideline Clearinghouse, [ http://www.guideline.gov/ search/search.aspx?term=multiple +sclerosis]
23. Important new Information-on Natalizumab (Marketed as Tysabri). U.S. Food and Drug Administration, 2006 http://www.accessdata.fda.gov/scripts/cdrh/ cfdocs/psn/transcript.cfm?show=52
24. FDA News Release. FDA Approves Resumed Marketing of Tysabri Under a Special Distribution Program. U.S. Food and Drug Administration, 2006 (updated June 6, 2006) http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ ucm108662.htm
25. Center Watch. Extavia (interferon beta 1-b). U.S. Food and Drug Administration, [ http://www.centerwatch.com/drug-information/fda-approvals/ drug-details.aspx?DrugID=1045 ]
26. Squinting through layers of fog: assessing the cost effectiveness of treatments for multiple sclerosis. Hawton A, Shearer J, Goodwin E, Green C, Appl Health Econ Health Policy 2013 11 4 331 341
27. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR task force on good research practices-modeling studies. Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, Luce BR, ISPOR Task Force of Good Research Practices-Modeling Studies, Value Health 2003 6 1 9 17 (Pubitemid 36228345)
28. Price increases and new drugs drive increased expenditures for multiple sclerosis. Schafer JA, Gunderson BW, Gleason PP, J Manag Care Pharm 2010 16 9 713 717
29. FDA Drug Safety Communication: New Risk Factor for Progressive Multifocal Leukoencephalopathy (PML) Associated With Tysabri (Natalizumab). U.S. Food and Drug Administration, 2012 http://www.fda.gov/Drugs/DrugSafety/ucm288186.htm
30. Risk Evaluation and Mitigation Strategy (REMS). Tysabri Outreach. Unified Commitment to Health (TOUCH®) Prescribing Program (MS & CD). U.S. Food and Drug Administration, http://www.fda.gov/downloads/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/UCM288126.pdf